HP Studies Worldwide
Evidence and History of Homeoprophylaxis
The history of homeoprophylaxis (HP) spans more than two centuries. Homeopathic practitioners and medical doctors and researchers have participated in studies and reported the results of using homeopathic preparations to prevent infectious diseases.
The reports below document the use of homeoprophylaxis in a range of countries and against numerous infectious diseases. Often reports describe results that exceeded 90% protection. They include individual clinical trials, large-scale public health interventions, long-term programs, and historical observations.
2020 — Cuban COVID-19 HP Measures
In 2020, Cuba implemented large-scale homeoprophylaxis as an additional measure during the COVID-19 pandemic. The program involved 953,416 families across 43 municipalities.
At the time, Cuba had reported 1,537 COVID-19-positive patients.
During the first month of use, 11 suspected adverse drug reaction (ADR) reports associated with PrevengHo-Vir were submitted. Of these, four (36.4%) were classified as moderate and seven (63.6%) as mild.
Source: Letter on observations with references.
2011 — Homeopathic Medicines for Influenza and Acute Respiratory Tract Infections in Children
Study: Homeopathic Medicines for Influenza and Acute Respiratory Tract Infections in Children: A Blind, Randomized, Placebo-Controlled Clinical Trial
A total of 600 children were recruited, and 445 completed the trial:
- 149 received the homeopathic complex.
- 151 received a placebo.
- 145 received InfluBio.
The number of symptomatic episodes was low, but a statistically significant difference was observed between the homeopathic groups and the placebo group (p<0.001).
During the first year following the intervention, 46 children (30.5%) in the placebo group experienced three or more episodes. No children in the Homeopathic Complex group experienced three or more episodes, while one child (1%) in the InfluBio group did.
The researchers concluded that the results suggested homeopathic medicines could minimize the number of symptomatic episodes.
Source: Published clinical trial, available through PubMed.
2009–2010 (published 2016) — Homeopathic Medicines for Influenza and Acute Respiratory Tract Infections in Children
Study: Homeopathic Medicines for Prevention of Influenza and Acute Respiratory Tract Infections in Children: Blind, Randomized, Placebo-Controlled Clinical Trial
A total of 600 children were recruited, and 445 completed the trial:
- 149 received the homeopathic complex.
- 151 received a placebo.
- 145 received InfluBio.
The number of symptomatic episodes was low, but a statistically significant difference was observed between the homeopathic groups and the placebo group (p<0.001).
During the first year following the intervention, 46 children (30.5%) in the placebo group experienced three or more episodes. No children in the Homeopathic Complex group experienced three or more episodes, while one child (1%) in the InfluBio group did.
The researchers concluded that the results suggested homeopathic medicines could minimize the number of symptomatic episodes.
Source: Homeopathy. 2016 Feb;105(1):71–77. doi:10.1016/j.homp.2015.02.006.
2007 — The Finlay Institute's Leptospirosis Campaign in Cuba
Following severe flooding in eastern Cuba in October and November 2007, approximately two million people were considered at risk of exposure to leptospirosis.
The Finlay Institute prepared a leptospira nosode, 200CH, from four circulating strains. Two doses were administered 7–9 days apart to approximately 2.4 million people, representing 4.8 million doses in total.
Coverage reached 95% of the at-risk population in the three provinces.
Surveillance data showed a decrease in morbidity beginning two weeks after the intervention. Mortality among hospitalized patients fell to zero. Confirmed cases remained low and below the levels expected based on historical trends and rainfall patterns.
Source: Homeoprophylaxis: Cuban Experiences on Leptospirosis, presentation to the International Meeting on Homeoprophylaxis, December 2008, Cuba.
2003–2005 — Kenyan Malarial Trial
Assie Pittendrigh conducted a malaria nosode trial in Kenya between 2003 and 2005, involving 33 volunteers.
Before the trial, 21 participants had experienced between one and three episodes of malaria during the preceding 18 months.
During the trial, one participant suspected that they might have malaria. However, a blood test did not confirm the infection. The participant recovered within hours, and malaria was considered unlikely. All other participants remained free of malaria during the trial.
Source: Partington, T. “Silent and Deadly: Prophylaxis and Treatment of Malaria.” Homeopathy in Practice, 2006, pp. 14–19.
2004 — Dr. Isaac Golden and the World's Longest HP Trials
Between 1985 and 2004, 2,342 children participated in Dr. Isaac Golden's long-term homeoprophylaxis trials. His PhD research was overseen by epidemiologists from Swinburne University in Melbourne.
The reported findings included:
- Homeoprophylaxis remedies were non-toxic and safe.
- Mild, temporary healing reactions occurred in fewer than 2% of participants.
- In relation to asthma, HP alone was reported to be 15 times safer than immunization and six times safer than doing nothing.
- In relation to eczema, HP was reported to be 7.4 times safer than immunization and 2.8 times safer than doing nothing.
- In relation to allergies, HP was reported to be five times safer than immunization and twice as safe as using no method.
- Asthma incidence among participants was 3%, compared with a national average of 19%.
- Behavioral problems were reported to be extremely low compared with other methods.
- Golden's program reported 90.4% efficacy against epidemic childhood diseases, including whooping cough, tetanus, polio, meningococcal disease, pneumococcal disease, and Hib.
Source: Dr. Isaac Golden's published research.
2002 — The Indian Government and Japanese Encephalitis
Beginning in 2000, the Indian government used Belladonna, Calcarea, and Tuberculinum in response to Japanese encephalitis (JE).
The reported incidence and death toll declined over the following years:
| Year | Cases | Deaths |
|---|---|---|
| 1999 | 1,036 | 203 |
| 2000 | 343 | 72 |
| 2001 | 33 | 4 |
| 2002 | 0 | 0 |
Source: The Times of India, July 27, 2003.
1998 — The Brazilian Government and the World's Largest HP Trials
In 1998, a Brazilian study repeated the meningococcal trial originally conducted by Eizayaga in 1974.
The study was conducted by two professors of medicine from the University Foundation in Blumenau, a specialist physician, and the Health City Secretary. It followed participants for one year.
The results were:
- Homeoprophylaxis group: 65,826 people, with four reported infections.
- Control group: 23,532 people, with 20 reported infections.
- Based on the control group's infection rate, 58 infections would have been expected in the HP group.
The reported efficacy was 95% during the first six months and 91% over the full year.
Source: Mroninski, C., Adriano, E., and Mattos, G. “Meningococcin, Its Protective Effect Against Meningococcal Disease.” Homoeopathic Links, Winter 2001, Vol. 14(4), pp. 230–234.
1996 — Indian Dengue Fever Trials
During a dengue hemorrhagic fever epidemic, a dengue fever nosode, 30C, was administered in the Delhi area.
A total of 39,200 people received the preparation, and 23,520 were followed up. Five symptomatic cases were reported among those followed.
The reported infection rate was 0.125%, compared with a stated normal infection rate of 50%. The total reported efficacy was 99.875%.
Source: CCRH News, 1996–1997.
1975 — Bildet's Hepatitis Research
Bildet studied the protective function of Phosphorus in different potencies on liver metabolism in rats with experimentally induced toxic hepatitis. Carbon tetrachloride was used to induce the hepatitis, and a positive effect was observed.
A repeat experiment in 1977 included histopathological examination and confirmed the original results.
In 1992, Gomez repeated the experiment and also confirmed the protective action. The study reported that high potencies and “potency chords” had a greater effect than lower potencies. After 72 hours, transaminase results were significant in all groups compared with the control group, with the exception of D10—the potency used in the Brazilian trials.
The renowned Brazilian homeopath Eizayaga also confirmed the hepatoprotective action of Phosphorus against various forms of hepatitis.
Sources:
- Bildet, J. Etude de l'action… Thesis, Bordeaux II, p. 2872, 1975.
- Gomez, J. M. “Aportación…” Medicina Biológica, 1, March, p. 414, 1992.
- Eizayaga, Francisco, MD. Treatise on Homeopathic Medicine. Ediciones Maracel, Buenos Aires, 1991.
1975 — Brazilian Meningococcal Trials
In 1974, Dr. Francisco Eizayaga conducted an original Brazilian trial using Meningococcinum 10C in liquid form.
The reported results were:
- Homeoprophylaxis group: 18,640 children treated, with four cases of meningococcal disease.
- Control group: 6,340 children, with 32 cases of meningococcal disease.
- Reported efficacy: 95%.
Source: Castro, D., and Nogueira, G. G. “Use of the Nosode Meningococcinum as a Preventive Against Meningitis.” Journal of the American Institute of Homeopathy, 1975; 68:211–219.
1974 (published 1975) — Dr. Francisco Eizayaga's Original Brazilian Meningococcal Trial
Dr. Francisco Eizayaga conducted an original Brazilian trial using Meningococcinum 10C in liquid form.
The reported results were:
- Homeoprophylaxis group: 18,640 children treated, with four cases of meningococcal disease.
- Control group: 6,340 children, with 32 cases of meningococcal disease.
- Reported efficacy: 95%.
Source: Castro, D., and Nogueira, G. G. “Use of the Nosode Meningococcinum as a Preventive Against Meningitis.” Journal of the American Institute of Homeopathy, 1975; 68:211–219.
1975 — Polio Myelitis Trials: Buenos Aires
In 1975, approximately 40,000 people in Buenos Aires received Lathyrus sativus as a polio prophylactic. None of those given the prophylactic reportedly developed polio.
Source: Eizayaga, Francisco. Treatise on Homeopathic Medicine, 1991.
1968–1970 — Krishnamurty's Report on Influenzinum
Krishnamurty conducted a survey in Indian factories and offices, comparing Influenzinum as a prophylactic against seasonal influenza with standard allopathic measures.
Nearly 20% of those receiving conventional treatment contracted influenza, compared with 6.5% of those receiving homeopathic treatment.
Among those who became ill, the homeopathically treated patients recovered more quickly. The number of workdays lost in the conventionally treated group was 8.5 times greater than in the homeopathic group.
Source: Krishnamurty. “Report on Influenzinum.” Hahnemannian Gleanings, 1970; 37:225–226.
1957 — Polio Myelitis Trials: Buenos Aires
During a polio epidemic in Buenos Aires in 1957, homeopathic doctors prescribed Lathyrus sativus, and thousands of doses were administered. None of those registered as having used the prophylactic reportedly developed polio.
Source: Eizayaga, Francisco. Treatise on Homeopathic Medicine, 1991.
1956 — Polio Myelitis Trials: Dr. Heisfelder
In 1956, Dr. Heisfelder immunized more than 6,000 children with Lathyrus sativus. No side effects were reported, and none of the children developed polio.
Source: Eisfelder, H. W. “Poliomyelitis Immunization: A Final Report.” Journal of the American Institute of Homeopathy, 1961.
1950 — Polio Myelitis Trials: Dr. Grimmer
In 1950, Dr. Grimmer of Chicago treated 5,000 young children prophylactically with Lathyrus sativus. None reportedly developed polio.
Source: Grimmer's collected works, 1996.
1950 — Polio Myelitis Trials: Taylor Smith
In Johannesburg in 1950, Taylor Smith reported that 82 people had been protected with homeopathic Lathyrus sativus. Twelve had direct contact with polio, and none became infected.
Source: British Homeopathic Journal, April 1950; 40(2):65–77.
1949–1975 — Polio Myelitis Trials
A series of reports from different locations described the use of Lathyrus sativus as a polio prophylactic. The individual reports are listed above in chronological order.
Source: History of Homeopathy in Epidemics.
1941–1942 — British Government Mustard Gas Trials
During World War II, the British government funded research at two centers, one in London and one in Glasgow. The research was conducted as a double-blind controlled trial.
Volunteers who had sustained burns from mustard gas received homeopathic treatment. Mustard Gas 30CH was used prophylactically, while Rhus tox 30CH and Kali bichromicum 30CH were used as treatments.
The treated group showed significant improvement. Opium 30CH, Cantharis 30CH, and Variolinum 30CH were also tested, but none of these preparations was found to be effective.
Source: Owen and Ives. “The Mustard Gas Experiments…” Proceedings of the 35th International Homeopathic Congress, 1982, pp. 258–259.
1941 — Patterson and Boyd's Diphtheria Trials
Patterson and Boyd repeated Chavanon's earlier experiment involving the Schick test and homeopathic treatment.
Of 33 children, 20 quickly produced antibodies, as indicated by the Schick test. All children treated in this way were Schick-negative within nine weeks, with some becoming negative within three weeks.
Source: Patterson, J., and Boyd, W. E. “Potency Action: A Preliminary Study of the Alteration of the Schick Test by a Homeopathic Potency.” British Homeopathic Journal, 1941; 31:301–309.
1938 — Dr. Chavanon's Historic Diphtheria Trials
Chavanon administered Diphtherinum 4M and 8M. After one to two months, antitoxin levels were measured.
Forty-five children who had initially tested Schick-positive (indicating no antibodies) subsequently tested Schick-negative (indicating the presence of antibodies).
Source: Chavanon, P. La Dipterie, 4th ed. St. Denis, Niort: Imprimerie, 1932.
1932 — Dr. Chavanon's Diphtheria Trials
Chavanon administered Diphtherinum 4M and 8M. After one to two months, antitoxin levels were measured.
Forty-five children who had initially tested Schick-positive (indicating no antibodies) subsequently tested Schick-negative (indicating the presence of antibodies).
Source: Chavanon, P. La Dipterie, 4th ed. St. Denis, Niort: Imprimerie, 1932.
1907 — Dr. Eaton's Smallpox Trials
In 1907, Variolinum 30C was administered to 2,806 people. Of these, 547 had definite exposure to smallpox.
Fourteen cases were reported following administration of Variolinum. The reported efficacy was 97%.
Source: Dr. Eaton's 1907 presentation to the American Institute of Homoeopathy.
1849 — Boenninghausen's Cholera Experience
During the European cholera epidemic of 1849, Dr. Clemens von Boenninghausen treated and prevented what he described as “untold numbers” of cholera infections using remedies recommended by Hahnemann.
The reported mortality rate among patients receiving conventional treatment was 54–90%, compared with 5–16% among Boenninghausen's patients.
Source: History of Homeopathy in Epidemics.
1838 — Prussian Government's Scarlet Fever Research
Hufeland, Surgeon-General of Prussia, reviewed the results of using Belladonna prophylactically against scarlet fever.
The results were considered sufficiently compelling that the Prussian government made the use of Belladonna compulsory during scarlet fever epidemics in 1838.
Source: Hufeland. “Prophylactic Power of Belladonna in Scarlet Fever.” Hufeland's Journal, 1826.
1831 — Hahnemann's Cholera Experience
Hahnemann described the use of Cuprum as a preventive measure against Asiatic cholera:
“The above preparation of copper, is the most certain preventive and protective remedy; those in health should take, once every week, a small globule of it (Cuprum 30C) in the morning fasting.”
Source: Samuel Hahnemann, MD. Cause and Prevention of the Asiatic Cholera, 1831. Archiv. f. hom. Helik., Vol. XI.
1801 — Hahnemann's Original Scarlet Fever Experience
Hahnemann wrote:
“Who can deny that the perfect prevention of the infection ... would offer infinite advantages over any other mode of treatment?”
In his report, 1,646 children were exposed, and 123 contracted the disease. The reported infection rate was under 1%, compared with a stated normal infection rate of 90%. The total reported efficacy was 99%.
Hahnemann also wrote:
“The remedy capable of maintaining the healthy uninfectable by the miasm of scarlatina, I was so fortunate as to discover.”
Sources:
- Dudgeon. Lectures on Theory & Practice of Homoeopathy.
- Hahnemann. Lesser Writings, 1801, p. 377.
Source: The Times of India, July 27, 2003.
1998 — The Brazilian Government and the World's Largest HP Trials
In 1998, a Brazilian study repeated the meningococcal trial originally conducted by Eizayaga in 1974.
The study was conducted by two professors of medicine from the University Foundation in Blumenau, a specialist physician, and the Health City Secretary. It followed participants for one year.
The results were:
- Homeoprophylaxis group: 65,826 people, with four reported infections.
- Control group: 23,532 people, with 20 reported infections.
- Based on the control group's infection rate, 58 infections would have been expected in the HP group.
The reported efficacy was 95% during the first six months and 91% over the full year.
Source: Mroninski, C., Adriano, E., and Mattos, G. “Meningococcin, Its Protective Effect Against Meningococcal Disease.” Homoeopathic Links, Winter 2001, Vol. 14(4), pp. 230–234.
1996 — Indian Dengue Fever Trials
During a dengue hemorrhagic fever epidemic, a dengue fever nosode, 30C, was administered in the Delhi area.
A total of 39,200 people received the preparation, and 23,520 were followed up. Five symptomatic cases were reported among those followed.
The reported infection rate was 0.125%, compared with a stated normal infection rate of 50%. The total reported efficacy was 99.875%.
Source: CCRH News, 1996–1997.
1975 — Bildet's Hepatitis Research
Bildet studied the protective function of Phosphorus in different potencies on liver metabolism in rats with experimentally induced toxic hepatitis. Carbon tetrachloride was used to induce the hepatitis, and a positive effect was observed.
A repeat experiment in 1977 included histopathological examination and confirmed the original results.
In 1992, Gomez repeated the experiment and also confirmed the protective action. The study reported that high potencies and “potency chords” had a greater effect than lower potencies. After 72 hours, transaminase results were significant in all groups compared with the control group, with the exception of D10—the potency used in the Brazilian trials.
The renowned Brazilian homeopath Eizayaga also confirmed the hepatoprotective action of Phosphorus against various forms of hepatitis.
Sources:
- Bildet, J. Etude de l'action… Thesis, Bordeaux II, p. 2872, 1975.
- Gomez, J. M. “Aportación…” Medicina Biológica, 1, March, p. 414, 1992.
- Eizayaga, Francisco, MD. Treatise on Homeopathic Medicine. Ediciones Maracel, Buenos Aires, 1991.
1975 — Brazilian Meningococcal Trials
In 1974, Dr. Francisco Eizayaga conducted an original Brazilian trial using Meningococcinum 10C in liquid form.
The reported results were:
- Homeoprophylaxis group: 18,640 children treated, with four cases of meningococcal disease.
- Control group: 6,340 children, with 32 cases of meningococcal disease.
- Reported efficacy: 95%.
Source: Castro, D., and Nogueira, G. G. “Use of the Nosode Meningococcinum as a Preventive Against Meningitis.” Journal of the American Institute of Homeopathy, 1975; 68:211–219.
1975 — Polio Myelitis Trials: Buenos Aires
In 1975, approximately 40,000 people in Buenos Aires received Lathyrus sativus as a polio prophylactic. None of those given the prophylactic reportedly developed polio.
Source: Eizayaga, Francisco. Treatise on Homeopathic Medicine, 1991.
1968–1970 — Krishnamurty's Report on Influenzinum
Krishnamurty conducted a survey in Indian factories and offices, comparing Influenzinum as a prophylactic against seasonal influenza with standard allopathic measures.
Nearly 20% of those receiving conventional treatment contracted influenza, compared with 6.5% of those receiving homeopathic treatment.
Among those who became ill, the homeopathically treated patients recovered more quickly. The number of workdays lost in the conventionally treated group was 8.5 times greater than in the homeopathic group.
Source: Krishnamurty. “Report on Influenzinum.” Hahnemannian Gleanings, 1970; 37:225–226.
1957 — Polio Myelitis Trials: Buenos Aires
During a polio epidemic in Buenos Aires in 1957, homeopathic doctors prescribed Lathyrus sativus, and thousands of doses were administered. None of those registered as having used the prophylactic reportedly developed polio.
Source: Eizayaga, Francisco. Treatise on Homeopathic Medicine, 1991.
1956 — Polio Myelitis Trials: Dr. Heisfelder
In 1956, Dr. Heisfelder immunized more than 6,000 children with Lathyrus sativus. No side effects were reported, and none of the children developed polio.
Source: Eisfelder, H. W. “Poliomyelitis Immunization: A Final Report.” Journal of the American Institute of Homeopathy, 1961.
1950 — Polio Myelitis Trials: Dr. Grimmer
In 1950, Dr. Grimmer of Chicago treated 5,000 young children prophylactically with Lathyrus sativus. None reportedly developed polio.
Source: Grimmer's collected works, 1996.
1950 — Polio Myelitis Trials: Taylor Smith
In Johannesburg in 1950, Taylor Smith reported that 82 people had been protected with homeopathic Lathyrus sativus. Twelve had direct contact with polio, and none became infected.
Source: British Homeopathic Journal, April 1950; 40(2):65–77.
1949–1975 — Polio Myelitis Trials
A series of reports from different locations described the use of Lathyrus sativus as a polio prophylactic. The individual reports are listed above in chronological order.
Source: History of Homeopathy in Epidemics.
1946 — Dr. Roux's Diphtheria Trials
Dr. Roux repeated Chavanon's experiment involving diphtheria and the Schick test.
The nosode reportedly provided laboratory confirmation of lasting immunity. Blood antitoxins appeared to remain present for up to five years following a single dose.
Source: Eizayaga, F. “Tratamiento Homeopatico de las Enfermedades Agudas y Su Prevension.” Homeopatia, 1985; 51(342):352–362.
1941–1942 — British Government Mustard Gas Trials
During World War II, the British government funded research at two centers, one in London and one in Glasgow. The research was conducted as a double-blind controlled trial.
Volunteers who had sustained burns from mustard gas received homeopathic treatment. Mustard Gas 30CH was used prophylactically, while Rhus tox 30CH and Kali bichromicum 30CH were used as treatments.
The treated group showed significant improvement. Opium 30CH, Cantharis 30CH, and Variolinum 30CH were also tested, but none of these preparations was found to be effective.
Source: Owen and Ives. “The Mustard Gas Experiments…” Proceedings of the 35th International Homeopathic Congress, 1982, pp. 258–259.
1941 — Patterson and Boyd's Diphtheria Trials
Patterson and Boyd repeated Chavanon's earlier experiment involving the Schick test and homeopathic treatment.
Of 33 children, 20 quickly produced antibodies, as indicated by the Schick test. All children treated in this way were Schick-negative within nine weeks, with some becoming negative within three weeks.
Source: Patterson, J., and Boyd, W. E. “Potency Action: A Preliminary Study of the Alteration of the Schick Test by a Homeopathic Potency.” British Homeopathic Journal, 1941; 31:301–309.
1938 — Dr. Chavanon's Historic Diphtheria Trials
Chavanon administered Diphtherinum 4M and 8M. After one to two months, antitoxin levels were measured.
Forty-five children who had initially tested Schick-positive (indicating no antibodies) subsequently tested Schick-negative (indicating the presence of antibodies).
Source: Chavanon, P. La Dipterie, 4th ed. St. Denis, Niort: Imprimerie, 1932.
1907 — Dr. Eaton's Smallpox Trials
In 1907, Variolinum 30C was administered to 2,806 people. Of these, 547 had definite exposure to smallpox.
Fourteen cases were reported following administration of Variolinum. The reported efficacy was 97%.
Source: Dr. Eaton's 1907 presentation to the American Institute of Homoeopathy.
1849 — Boenninghausen's Cholera Experience
During the European cholera epidemic of 1849, Dr. Clemens von Boenninghausen treated and prevented what he described as “untold numbers” of cholera infections using remedies recommended by Hahnemann.
The reported mortality rate among patients receiving conventional treatment was 54–90%, compared with 5–16% among Boenninghausen's patients.
Source: History of Homeopathy in Epidemics.
1838 — Prussian Government's Scarlet Fever Research
Hufeland, Surgeon-General of Prussia, reviewed the results of using Belladonna prophylactically against scarlet fever.
The results were considered sufficiently compelling that the Prussian government made the use of Belladonna compulsory during scarlet fever epidemics in 1838.
Source: Hufeland. “Prophylactic Power of Belladonna in Scarlet Fever.” Hufeland's Journal, 1826.
1831 — Hahnemann's Cholera Experience
Hahnemann described the use of Cuprum as a preventive measure against Asiatic cholera:
“The above preparation of copper, is the most certain preventive and protective remedy; those in health should take, once every week, a small globule of it (Cuprum 30C) in the morning fasting.”
Source: Samuel Hahnemann, MD. Cause and Prevention of the Asiatic Cholera, 1831. Archiv. f. hom. Helik., Vol. XI.
1801 — Hahnemann's Original Scarlet Fever Experience
Hahnemann wrote:
“Who can deny that the perfect prevention of the infection ... would offer infinite advantages over any other mode of treatment?”
In his report, 1,646 children were exposed, and 123 contracted the disease. The reported infection rate was under 1%, compared with a stated normal infection rate of 90%. The total reported efficacy was 99%.
Hahnemann also wrote:
“The remedy capable of maintaining the healthy uninfectable by the miasm of scarlatina, I was so fortunate as to discover.”
Sources:
- Dudgeon. Lectures on Theory & Practice of Homoeopathy.
- Hahnemann. Lesser Writings, 1801, p. 377.
Conclusion
The studies and historical reports presented here represent a significant body of evidence spanning more than two centuries and including work conducted under the oversight of governments and universities.
Taken together, these reports document the use of homeoprophylaxis in a wide range of countries and against numerous infectious diseases. They support the consideration of HP as an alternative to standard vaccination in circumstances where vaccination is undesirable, unnecessary, or impossible.
References and Notes
[i] "The findings of efficacy studies have not demonstrated a direct correlation between antibody response and protection against pertussis disease.”
MMWR March 28, 1997/Vol.46/No. RR-7, pg. 4
[ii] References concerning Gardasil and reported antibody responses include Taranger et al., The Lancet, and publications in the New England Journal of Medicine and JAMA.